Bridging tumor moats with potent drug delivery particles
Despite herculean efforts, cancer remains a formidable disease, with each malignant subtype responding differently to therapeutics. One hurdle specific to treating solid tumors is a protective layer called an extracellular matrix that can prevent chemotherapeutic agents from penetrating the tumor's core. Scientists now report results in ACS' Chemistry of Materials showing that, by cloaking anti-cancer drugs in a specially designed particle, they could target and destroy tumor cells deep inside a malignant mass in vitro.
For tumors that can't be extracted with surgery, radiation and chemotherapy are the treatments of choice, but both can involve serious side effects due to a lack of specificity: They'll kill healthy cells along with malignant ones. Researchers have long known that, thanks to the unique blood vessel architecture surrounding tumors, nanoparticles can easily pass into the cancer zone, offering a potential route for the specific delivery of chemotherapies to cancer cells. However, efforts to exploit this phenomenon have fallen short, with experimental drug-loaded particles failing because they can't get through the dense extracellular matrix or they lose the therapeutic payload en route to the tumor's interior. Alejandro Baeza, C. Jeffrey Brinker, Maria Vallet-Regi and colleagues addressed this shortcoming by developing a brand-new type of particle.
The researchers created a "protocell," a nanoparticle that can carve through the extracellular matrix, delivering cell-killing doses of drug to the deepest tumor regions. To develop the protocell, the team started with a mesoporous silica skeleton with a high internal surface area that can contain a large amount of drug. They surrounded this skeleton with a lipid bilayer outfitted with an array of tools to help the protocell deliver its drug arsenal to the desired locale, including enzymes that cleave collagen, a major component of the tumor's extracellular matrix. The protocell also features pH-sensitive ligands that trigger the release of the drug upon entry into the relatively acidic interior of a cell, ensuring the medication is only delivered where needed. The researchers tested the protocells in a 3-D cell culture model of a solid tumor, showing that the protocell penetrates and destroys malignant cells better than drug-loaded protocells without the enhanced toolkit.e potential to one day treat cancer and other diseases in the female reproductive tract.
The authors acknowledge funding from the European Research Council, Sandia National Laboratories and the Leukemia and Lymphoma Society.
The abstract that accompanies this study is available here.
The American Chemical Society, the world's largest scientific society, is a not-for-profit organization chartered by the U.S. Congress. ACS is a global leader in providing access to chemistry-related information and research through its multiple databases, peer-reviewed journals and scientific conferences. ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies. Its main offices are in Washington, D.C. and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact email@example.com.
Follow us on Twitter | Facebook